(Q33628626)

English

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies (English)

1 reference

Europe PubMed Central

28 July 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

Gavin Giovannoni

2

object named as

G Giovannoni

1 reference

Europe PubMed Central

28 July 2017

author name string

E Havrdova

1

1 reference

Europe PubMed Central

28 July 2017

R Gold

3

1 reference

Europe PubMed Central

28 July 2017

R J Fox

4

1 reference

Europe PubMed Central

28 July 2017

L Kappos

5

1 reference

Europe PubMed Central

28 July 2017

J Theodore Phillips

6

1 reference

Europe PubMed Central

28 July 2017

M Okwuokenye

7

1 reference

Europe PubMed Central

28 July 2017

J L Marantz

8

1 reference

Europe PubMed Central

28 July 2017

publication date

22 March 2017

1 reference

Europe PubMed Central

28 July 2017

European Journal of Neurology

1 reference

Europe PubMed Central

28 July 2017

24

1 reference

Europe PubMed Central

28 July 2017

5

1 reference

Europe PubMed Central

28 July 2017

726-733

1 reference

Europe PubMed Central

28 July 2017

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Regression Analysis of Grouped Survival Data with Application to Breast Cancer Data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5413827

14 July 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1111%2FENE.13272

21 January 2018

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

1 reference

https://api.crossref.org/works/10.1111%2FENE.13272

21 January 2018

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

1 reference

https://api.crossref.org/works/10.1111%2FENE.13272

21 January 2018

Identifiers

10.1111/ENE.13272

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33628626&oldid=1535121439"